AstraZeneca's Rough Monday: Ultomiris Fails, Pipeline Questions Mount

AstraZeneca kicked off Monday with a double dose of bad news from the lab. The pharma giant revealed that its rare disease drug Ultomiris (ravulizumab) failed a late-stage trial in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) — a devastating blood vessel complication that can follow stem cell transplants. The drug did not achieve statistical significance for event-free survival at 26 weeks, though it showed a trend toward...